Metraipolis › archive › dc_85bc3410b658

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus… — Europe PMC PMID:41536373

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41536373
DOI
10.7759/cureus.99214
License (as archived)
solo-consultazione
Archived
2026-11-07T11:00:30.350Z
SHA-256 of the archived text
c7f254cb02d7f6797e9733ef87e5874ee1bc73094994f046e794c840209ec0ea
Stable URL of this page
https://metraipolis.com/documento/dc_85bc3410b658

How to cite

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus… — Europe PMC PMID:41536373 — Europe PMC (en), https://europepmc.org/article/MED/41536373 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_85bc3410b658 (Metraipolis archive dc_85bc3410b658, sha256 c7f254cb02d7f6797e9733ef87e5874ee1bc73094994f046e794c840209ec0ea)
BibTeX
@misc{dc85bc3410b658,
  title = {Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus… — Europe PMC PMID:41536373},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41536373},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_85bc3410b658; sha256 c7f254cb02d7f6797e9733ef87e5874ee1bc73094994f046e794c840209ec0ea},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41536373. Agents can read the archived copy with the MCP tool read_document.